Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

As the company restructures, it will pivot to selling genetic tests to consumers and using that data for research. Also: medicinal and tech advancements in cancer care; research monkeys roundup.

British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the end of ...